103788-72-3Relevant academic research and scientific papers
Amino-thiazolidinediones useful in the treatment of insulin resistance and hyperglycemia
-
, (2008/06/13)
This invention provides compounds of Formula I having the structure wherein: R is hydrogen or alkyl of 1-6 carbon atoms; A is R1, R2, R3are each, independently, hydrogen, alkoxy of 1-6 carbon atoms, thioalkyl of 1-6 carbon
Ether and amide compounds and preparation of thereof as antidiadetics.
-
, (2008/06/13)
Ether and amide derivatives are disclosed, which are represented by the following formula (I) and its pharmaceutical acceptable salt, and which are useful for the treatment of diabetes. 1(with the provisos that (i) when A is —O—, then n is 2 or 3 (ii) when A is 2then n is 1 or 2. R3 is OH—, CH3SO2NH—, CF3SO2NH—, CH3SO2NHCH2—, CF3SO2NHCH2—, HOOC—, CH3OOC—, 3HOOC—CH2SO2NH—, CF3—CH2SO2NH—, 4R8—NHSO2—, R8—NHSO2—CH2—, HOOC—CH2—O—, HSO3N=CH—, or R9—SO2NHCO—; R4 is H, OH, O-alkyl or O—CH2OCH3; R5 is H, halogen atom, —CH2COOH or OH; R6 and R7 are hydrogen, t-butyl or pyrolidyl; R8 is hydrogen or lower alkyl; R9 is alkyl or thienyl; R10 is lower alkyl) or a pharmaceutically acceptable salt.
Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents
Sohda,Mizuno,Momose,Ikeda,Fujita,Meguro
, p. 2617 - 2626 (2007/10/02)
In the course of further chemical modification of the novel antidiabetic pioglitazone (AD-4833, U-72, 107), a series of 5-[4-(2- or 4- azolylalkoxy)benzyl- or -benzylidene]-2,4-thiazolidinediones was prepared and evaluated for hypoglycemic and hypolipidemic activities in insulin-resistant, genetically obese, and diabetic KKA(y) mice. Replacement of the 2-pyridyl moiety of pioglitazone by a 2- or 4-oxazolyl or a 2- or 4-thiazolyl moiety greatly enhanced in vivo potency. The corresponding 5-benzylidene-type compounds, in which a methine was used as a linker between the benzene ring and the thiazolidinedione ring, also had potent biological activity. Among the compounds synthesized, 5-[4-[2-(5-methyl-2-phenyl-4- oxazolyl)ethoxy]benzyl]-2,4-thiazolidinedione (18) exhibited the most potent activity, more than 100 times that of pioglitazone. The synthesis and structure-activity relationships for this novel series of derivatives are detailed.
